Douglas J. Manion - Mar 17, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Pres and CEO, Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Mar 17, 2023
Transactions value $: $49,532
Form type: 4
Date filed: 3/17/2023, 05:03 PM
Previous filing: Mar 9, 2023
Next filing: Aug 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Purchase	$49.5K	+6.3K	+96.92%	$7.86	12.8K	Mar 17, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $7.86 to $7.8641, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $7.86 to $7.8641, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.